Advertisement

Topics

ADDING and REPLACING Stratasys Releases Fourth Quarter and Full Year 2016 Financial Results

09:42 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Company reports $175.3 million in revenue for Q4 with an increase in recurring revenues GAAP net loss of $14.8 million, or ($0.30) per diluted share, and non-GAAP net income of $7.8 million, or $0.15 per diluted share, ...

Other Sources for this Article

Stratasys Investor Relations
Shane Glenn, 952-294-3416
Vice President - Investor Relations
shane.glenn@stratasys.com

NEXT ARTICLE

More From BioPortfolio on "ADDING and REPLACING Stratasys Releases Fourth Quarter and Full Year 2016 Financial Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...